tbuckley/cabot-search huggingface dataset:
Perceived sexual dysfunction in breast cancer survivors.
Authors: Elizabeth Anne Block, Terri Ann Zomerlei, Jessica Keto, Jamie Caughran
Journal: Journal of Clinical Oncology (2012)

67 Background: Sexual dysfunction after breast cancer treatment has been well documented in the literature. However, the degree of dysfunction and how best to address this issue in survivors is less clear. We sought to determine the prevalence of patient perceived sexual dysfunction in breast cancer patients in our patient population. Methods of addressing dysfunction, influence on satisfaction, and interfering factors were indentified. Methods: An IRB-approved survey study of English speaking female breast cancer patients stage 0-III, ages 20 to 80, from 2008-2011 was performed. A 30 question survey containing components related to demographic, breast cancer treatment, perceived impact on sexual function due to treatment, overall satisfaction with intimate relationship, and factors interfering with intimate relationships was used. Results: Of the 407 women meeting inclusion criteria, 103 returned an informed consent, and 83 completed the survey. A total of 47 (64%) of responders felt that treatment had a negative impact on their sexual function. Of those, only 23% discussed the issue with a care provider while 60% desired a physician initiated conversation. A negative perception was associated with decreased satisfaction with intimate relationships (p&lt;0.001). The prevalence of treatment related interfering factors such as fatigue, hot flashes, scars, dysparunia, and breast tenderness were cited most frequently. Of these, only the presence of scars was significantly associated with a perceived negative impact on intimate relationships (p&lt;0.04). Women treated with breast conservation were less likely to perceive a negative impact than mastectomy patients (p=0.036). Conclusions: Patient perceived sexual dysfunction is a documented consequence of breast cancer treatment. Our data demonstrates that patients do not feel this issue is addressed during routine care. However, the majority of patients want this issue discussed with their physicians. Sexual dysfunction is independent of age, time post surgery, and interfering factors making it difficult to identify high risk populations. Therefore, sexual dysfunction should be identified in breast cancer patients during follow-up with interventions made when appropriate.
Abstract 12311: Side Branch Angle Influences the Neointimal Coverage of Drug-Eluting Stent in Coronary Bifurcation Lesions: An Optical Coherence Tomography Study
Authors: Makoto Watanabe, Shiro Uemura, Youko Dote, Yu Sugawara, Yutaka Goryo, Tomoya Ueda, Satoshi Okayama, Yoshihiko Saito
Journal: Circulation (2014)

Background: Stent implantation for coronary bifurcation is intrinsically accompanied with inappropriate strut apposition around side branch (SB), which has potential risk for future development of stent thrombosis. Previous experimental studies indicated that side branch angle (SBA) influences the local flow turbulence and wall shear stress. The purpose of this study was to investigate the relation between SBA and the neointimal coverage of drug-eluting stent (DES) which were implanted in coronary bifurcation lesions. Methods: Forty-seven bifurcation lesions treated with DES were evaluated with FD-OCT in 39 patients (mean age; 65.7±13.9 y.o) at follow-up angiography. Each lesions were divided into the bifurcation lesions without kissing balloon technique (KBT) after stent implantation (non-KBT group; 28 lesions) and those with KBT (KBT group; 19 lesions). Neointimal coverage was assessed based on cross-sectional OCT images containing SB at 0.4mm interval, and separately evaluated in terms of jailing struts over the SB ostium (SO) and non-jailing struts attaching to the vessel wall (VW). BA was measured on the longitudinal reconstruction images of FD-OCT before stent implantation. Incidence of uncovered struts and neointimal thickness were measured. Results: In non-KBT group, the percentage of uncovered struts was significantly higher in lesions with SBA≦60°compared with those with SBA&gt;60°at both SO and VW region (56.9±39.8% vs. 25.6±26.8%, p&lt;0.05; 10.6±7.6% vs. 3.3±4.4%, p&lt;0.01, respectively) and significant negative correlation was found between SBA and the percentage uncovered struts at both SO and VW regions (r=–0.55, p&lt;0.01; r=–0.47, p&lt;0.05, respectively). In KBT group, the percentage of uncovered struts was not significant difference between lesions with SBA≦60°and those with SBA&gt;60°at both SO and VW region (36.7±35.3% vs. 36.6±34.8%; 10.9±10.4% vs. 8.6±12.7%, respectively) and no correlation was found between SBA and the percentage of uncovered struts at both SO and VW region. Conclusions: The neointimal coverage of DES was affected by in bifurcation lesion without KBT, but is not affected in bifurcation lesion with KBT. KBT has potential benefit for neointimal coverage of DES at coronary bifurcation lesion with narrow SBA.
Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study.
Authors: G E Goodman, J Crowley, R B Livingston, S E Rivkin, K Albain, J H McCulloch
Journal: Journal of Clinical Oncology (1991)

Between March 1986 and May 1988, the Southwest Oncology Group enrolled 58 previously untreated patients with limited small-cell lung cancer on a treatment program that administered high-dose cyclophosphamide (150 mg/kg) as late intensification. Treatment consisted of induction chemo-radiotherapy, (weeks 1 to 11), consolidation chemotherapy (weeks 11 to 18), and intensification (week 18). Median age was 61.5 years. Eighty-nine percent of patients had a Southwest Oncology Group (SWOG) performance status of 0-1. Twenty-one patients completed all prescribed treatments. There were seven treatment-related deaths, four as a result of intensification. Fifty-six patients are available for response analysis. Thirty-two patients achieved a complete remission (CR) (57%) and fifteen achieved a partial remission (PR) (26%). Median survival for all patients is 11.1 months. Among the 21 patients who received intensification, nine remain alive in a CR with a median survival of 27 months. This sequence of treatments was not associated with a survival advantage for the group as a whole, possibly because of the toxicity of induction and consolidation treatment and the delayed administration of high-dose cyclophosphamide.
The management of small asymptomatic pancreatic neuroendocrine tumors: A matched case-control study.
Authors: Eran Sadot, Diane Lauren Reidy, Laura H. Tang, Mithat Gonen, Michael Ian D'Angelica, Ronald P. DeMatteo, T. Peter Kingham, William R. Jarnagin, Peter J. Allen
Journal: Journal of Clinical Oncology (2015)

239 Background: Overdiagnosis and overtreatment has become an evolving challenge for several cancer sub-types. We hypothesized that a substantial portion of incidentally diagnosed small pancreatic neuroendocrine tumors(PanNET) are overtreated as a result of overdiagnosis and that non-operative management may be reasonable for selected patients. Methods: Consecutive patients evaluated for incidentally discovered, sporadic, stage I-II PanNET were analyzed retrospectively. Diagnosis was determined either by pathology or unequivocal imaging characteristics. Patients selected for radiographic surveillance (RS) were matched with patients who underwent resection based on tumor size at initial imaging. Clinicopathological characteristics were compared between the groups. Results: During the study period (2000-2013), RS was recommended for 80 patients, and 79 matched patients underwent resection (resection group). Pathologic diagnosis was obtained in 42 (53%) of the 80 RS patients. Median initial tumor size was similar between the RS vs resection groups (1.2cm (0.8-1.7) vs 1.3 cm (1-1.9), respectively, p=0.4). The resection group was younger and had a longer median follow-up compared to the RS group (58 vs 65 years, p&lt;0.001; 50 vs 29 months, p=0.006; respectively). At the time of last follow-up of the RS group, median tumor size had not changed (1.2cm, p=0.4), no patient had developed metastases, and no patient had experienced radiographic changes in the primary tumor that prompted resection. Within the resection group, low-grade (G1) pathology was recorded in 74 (95%) tumors, one patient had node positive disease, and five developed recurrence (6%). The postoperative complication rate was 36%. No patient in either group died from disease. Death from other causes occurred in 7 out of 159(4%) patients. Conclusions: In this study, no patient who was selected for observation developed metastases or died from disease after a median follow-up of almost 2.5 years.Radiographic surveillance for stable, small, incidentally discovered PanNETs is reasonable in selected patients.
P781Assessment of the accuracy and reproducibility of left ventricular mass and volumes measurements in mice using an 11.7T MRI machine
Authors: L Vanhoutte, H Esfahani, O Feron, JL Balligand, B Gallez, S Moniotte
Journal: Cardiovascular Research (2014)

Background: In cardiovascular imaging, variations within and between observers, and between different acquisitions remain an important issue when interpreting in vivo data. Though there has recently been an increasing interest in ultra-high field MRI to characterize rodent models of cardiovascular diseases, reports concerning its reproducibility are scarce. The purpose of our work was to evaluate the intraobserver, interobserver and interexperiment variability of left ventricular (LV) mass and volumes measurements in mice using an 11.7T MRI scanner and to assess the validity of our results by comparing them with ex vivo measurements. Methods: 29 C57Bl6/J male mice aged 10-18 weeks were studied, including animals having previously undergone minimally invasive transverse aortic constriction. Imaging was performed on an 11.7 T MRI system (Biospec, Bruker, Germany). The LV systolic function was assessed from a stack of short-axis views obtained with a FLASH-cine sequence covering the entire ventricles. Using a dedicated software (SegmentTM, Medviso, Sweden), the following volumes (μl) were determined : end-diastolic, end-systolic and stroke volumes. LV ejection fraction (in %) and LV mass (mg) were subsequently deduced. Interobserver (n=24), intraobserver (n=24) and interexperiment (n=12) reproducibility were studied with the Bland and Altman method. LV masses obtained with the MRI were compared with ex vivo morphometric data. Results: Reproducibility was excellent for the LV mass and end-diastolic volume (EDV) (coefficient of variability - CoV - between 5,38 and 11,77%), good for end-systolic volume (ESV) (CoV between 15,24 and 16.81%) and moderate for data related to the smallest volumes, i.e. the stroke volume (SV) and ejection fraction (EF) (CoV between 14,73 and 20,93%). Importantly, we demonstrated an excellent correlation between LV mass measurements by weighing or imaging, with a Pearson correlation (r) of 0.92. Conclusions: In our study, we show that the mouse LV systolic function can be longitudinally assessed on an 11.7T MRI scanner, with excellent reproducibility of LV mass and EDV and a good correlation of LV mass results with ex vivo morphometric measurements. However, we highlight the need to take into account some shortcomings when interpreting MRI data, like moderate reproducibility of very small volumes, focusing on parameters that are the most reproducible or using alternative sequences with better resolution.
Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
Authors: T. E. Witzig, P. H. Wiernik, T. Moore, C. Reeder, C. Cole, G. Justice, H. Kaplan, M. Voralia, D. Pietronigro, J. M. Vose
Journal: Journal of Clinical Oncology (2009)

8560 Background: Lenalidomide has shown activity in a wide range of hematological malignancies. We conducted a phase II trial of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL). Methods: Patients with relapsed or refractory indolent NHL were eligible, with no limit on the number of previous therapies. Oral lenalidomide 25 mg was self-administered once-daily on days 1–21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression. The primary endpoint was overall response rate (ORR), with secondary endpoints of response duration, progression-free survival (PFS), and safety. Results: Forty-three patients were enrolled and were evaluable for response and safety. Patients had received a median of 3 prior systemic therapies (1–17) and half of all patients were refractory to their last therapy. The ORR was 23% (10/43), including a complete response (CR) or unconfirmed CR (CRu) rate of 7%. The median time to first response was 3.6 months (1.7–4.2) and the median time to CR or CRu was 4.2 months (1.9–11.1). Twenty-seven percent (6/22) of patients with follicular lymphoma grade 1 or 2, and 22% (4/18) of patients with small lymphocytic lymphoma responded to therapy. The median duration of response has not reached, but is longer than 16.5 months with 7 of 10 responses ongoing at 15–28 months. Median PFS was 4.4 months (2.5–10.4). Adverse events were consistent with the known safety profile of lenalidomide and manageable; the most common grade 3 or 4 adverse events were neutropenia (30% and 16%, respectively) and thrombocytopenia (14% and 5%, respectively). Conclusions: Oral lenalidomide monotherapy produces durable responses with manageable side effects in relapsed or refractory indolent NHL and warrants further investigation in the treatment of indolent NHL. [Table: see text]
Intraperitoneal Application of the Trifunctional Monoclonal Antibody Catumaxomab in Outpatients with Malignant Ascites Related to Various Epithelial Tumors
Authors: C.M. Kurbacher, O. Horn, S. Herz, C. Schweitzer, N. Nymbach, P. Hinz, S. Sperling, J.A. Kurbacher, G. Kollberg
Journal: Annals of Oncology (2014)
GPs face sevenfold rise in fees to healthcare regulator
Authors: Ingrid Torjesen
Journal: BMJ (2015)

General practices in England will be hit by a sevenfold increase in the fees they must pay to the Care Quality Commission over two to four years, under plans proposed by the watchdog to claw back its full chargeable costs from healthcare providers.

The CQC’s fee for a general practice with between 5000 and 10 000 registered patients that operates at one location would rise from £725 (€1015; $1120) a year for 2015-16 to £4839 a year, the watchdog has said. The annual fee for general practices with premises at five locations would rise from £2681 to £17 839.

The proposed increases would be implemented over two or four years. If implementation were over two years, for 2016-17 general practices would have to pay more than three times the fee they paid this …
A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum
Authors: K. Y. Chung, I. Gore, L. Fong, A. Venook, P. Dorazio, D. Healey, D. Pavlov, L. B. Saltz
Journal: Journal of Clinical Oncology (2007)

3035 Background: The antitumor activity of antibodies to cytotoxic T lymphocyte-associated antigen 4 (CTLA4) has been demonstrated in a variety of murine tumor models, including rejection of established tumors and secondary exposure to tumor cells. This suggests that blockade of the inhibitory effects of CTLA4 can promote effective antitumor immune responses. CP-675,206 has also been shown to induce durable tumor responses in patients (pts) with metastatic melanoma in phase 1 and phase 2 clinical studies. The purpose of this study was to assess safety and efficacy of CTLA4 blockade with the fully human mAb CP-675,206 as single-agent therapy in pts with relapsed/ refractory colorectal cancer. Methods: A single-arm, multicenter, phase II trial of CP-675,206 was conducted in pts with measurable adenocarcinoma of the colon or rectum failing standard treatments and with an ECOG performance status of 0 or 1. Patients received 15 mg/kg Q90 days via IV infusion until disease progression. The primary objective was response rate by RECIST criteria. Secondary objectives included safety, duration of response, progression-free survival, and overall survival. Results: A total of 47 pts who received a median of 4 previous therapies (range, 1 to 9) were treated, and 46 experienced disease progression or death because of disease before reaching the planned second dose at 3 months. Grade 3 or 4 adverse events attributed to study drug were limited to diarrhea (n = 3, 6.4%) and idiopathic thrombocytopenia purpura (n = 1, 2.1%). Four pts (8.5%) had grade 2 diarrhea. Four pts received steroids and 2 received infliximab. One patient was removed for toxicity (diarrhea in the setting of what appeared to be treatment-related ulcerative colitis that was responsive to steroids). One patient (2%; 95% CI = 0%, 11%) had a stable ovarian mass and a substantial regression in an adrenal mass. This patient is continuing on study and has received a second dose. Conclusions: In heavily pretreated pts with colorectal cancer and good performance status, CP- 675,206 was tolerable. However, in this setting, CP-675,206 at 15 mg/kg did not demonstrate substantial single-agent activity. No significant financial relationships to disclose.
Comparison of squamous cell carcinoma of the canal anal (SCCA) prognosis in patients infected or not by human immunodeficiency virus (HIV)
Authors: N. Mathieu, T. Aparicio, F. Roudot-Thoraval, N. Lemarchand, P. Bauer, C. Hennequin, E. Mitry, C. Romelaer, L. Abramowitz, I. Sobhani
Journal: Journal of Clinical Oncology (2007)

4632 Background: Incidence of SCCA is increasing promoted by HIV infection. Previous small series of SCCA revealed a worst prognosis in HIV+ than in HIV- patients. Few data are available since the use of highly active antiretroviral therapy (HAART) in HIV patients. The aim of the study was to compare clinical outcome of patients recently treated for SCCA according to HIV status. Methods: Retrospective study in 6 hospitals. all consecutive patients treated for SCCA from January 1998 to October 2004 were included. Clinical outcome and pattern of care according to HIV status were compared. Results: 151 patients were included, 44 (29%) of them were HIV infected. Median follow-up was 27 (16–44) months. HIV+ patients were youngest (45 vs 62 years old, p&lt;0.001) and only male (100% vs 27%, p&lt;0.001). There were no significant difference in tumor stage I : 37.5 vs 25%, II : 48 vs 42.5%, IIIa : 7.5 vs 16.5%, IIIb : 12.5 vs 5% and IV : 0 vs 6% according to HIV+ or HIV- respectively. The treatments performed in HIV+ and HIV- patients were: Pelvic radiotherapy in 86 vs 91% (ns) delivering a median dose of 48 and 46 Gray. A boost in reduced fields or brachytherapy was performed in 58% vs 64% (ns). Concomitant chemotherapy (5-fluorouracile and cisplatin) was administered in 52% vs 56% (ns). Dose intensity of 5-fluorouracile and cisplatin was similar in both group. Grade 3–4 toxicity of chemoradiotherapy was observed in 11% vs 10% (ns). Complete response was obtained in 82 vs 75% (ns) and surgery (colostomy or abdominoperineal resection) was performed in 2.4% vs 7.6% of the patients (ns). During the follow-up local or metastatic recurrence occurred in 32% vs 22% of the patients (ns). The 3 years disease free survival were 77% vs 67% (ns) and 3 years overall survival were 85% and 84% (ns). Among HIV+ patients, 42/44 were on HAART, the survival was not modified by the duration of infection, viral load and CD4 count. Conclusions: The clinical outcome of HIV+ patients with SCCA is now similar to HIV- patients. The same therapeutic guidelines should be applied in both population. This improvement of prognosis is probably due to extensive use of HAART in HIV+ patients. No significant financial relationships to disclose.
O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
Authors: H. Dvory-Sobol, D. Wyles, W. Ouyang, K. Chodavarapu, J. McNally, W. Cheng, S. Shafran, A. Mangia, C. Schwabe, M.D. Miller, H. Mo
Journal: Journal of Hepatology (2015)
Tumor c-MET expression does not predict the risk of venous thromboembolism in cancer patients
Authors: I. Rabinowitz, H. Sayar, J. Bunning, T. Bocklage, S. Lee, E. Libby
Journal: Journal of Clinical Oncology (2008)

22114 Background: Experiments in genetically engineered mice suggest an association between the tumor expression of the MET proto- oncogene (c-MET) and venous thromboembolism (VTE) (Boccaccio C, et al. Nature. 2005; 434:396–400). This retrospective study investigated this association in cancer patients. Methods: The medical records of patients in the Coumadin clinic were reviewed. A total of 95 had a diagnosis of cancer. Thirty six patients were excluded as their VTE was suspected to be secondary to identifiable predisposing factors such as central lines, tumor related pressure effects, or putative thrombogenic treatments. We then searched the tumor registry for age, gender and tumor matched controls. Thirty five cancer patients with documented VTE and no clinically relevant predisposing factors were retrospectively compared with 35 matched cancer patients without VTE who served as controls. Pathology specimens of tumors from all patients and controls were stained by immunohistochemistry (IHC) for c-MET. The IHC-processed slides were read as 0 (negative), 1+ (equivocal), and 2+ (positive). The two independent pathologists were binded with respect to the VTE status of the patients. The c-MET positivity was compared between the two groups. Fisher's exact test was used to compute the association between the incidence of VTE and positive c-MET staining Results: There was no significant difference between the two groups for c-MET expression (7, 10, and 18 VTE patients versus 7, 11, and 17 controls with 0, 1+, and 2+ c-MET expression, respectively; p=1.0). Conclusion: Although pre-clinical studies indicate a possible association between c-MET expression and a relative hypercoagulable state in cancer patients, this retrospective study did not confirm such a correlation. A larger study may be needed to confirm these results. No significant financial relationships to disclose.